ARTICLE | Clinical News
Timapiprant: Completed Phase III enrollment
October 3, 2016 7:00 AM UTC
Eleventa and Oxagen announced the completion of enrollment of 212 patients in a double-blind, placebo-controlled, Russian Phase III trial evaluating 50 mg oral timapiprant once daily for 12 weeks. Ato...